fda warning letter bpc-157 compounding Regulatory Alert: FDA's April 2026 Update on and GHK-Cu – Holt Law An FDA Committee Just Voted

Consideration GLP-1 (Semaglutide) GLP-1 + GIP (Tirzepatide) New to medical weight loss programs Want to target appetite regulation and digestion speed Need added support for insulin response & fat metabolism Have tried GLP-1 therapy before without desired results Prefer to start with one mechanism before adding a second Interested in dual-hormone approach for multiple pathways 2x weekly dosing and personalized guidance Which GLP weight loss program is right for you

PMID: 158 AtarashiKTanoueTShimaTImaokaAKuwaharaTMomoseYet al

This dual action creates conditions favorable for slow-wave sleep, the deepest and most restorative sleep phase

The types of autoimmune CTDs that are associated with the development of ILD are systemic sclerosis, rheumatoid arthritis, idiopathic inflammatory myositis (polymyositis-dermatomyositis and anti-synthetase syndrome), primary Sjogren syndrome, mixed connective tissue disease, and systemic lupus erythematosus, with various frequency (Table 1) (2)